GlobeNewsWire
21 Nov 2025, 14:01 UTC · 51w ago
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
Impact · against what's priced in
MAIA's reported 17.8-month overall survival in third-line NSCLC patients and the commencement of Phase 3 screening are significant clinical de-risking events. While the single 30-month survival case is anecdotal, the overall data suggests a breakthrough potential compared to the 6-month standard of care.
- MAIA+0.70
No priced-in read yet





